期刊文献+

金丝桃苷通过抑制HSP90AA1抑制乳腺癌细胞增殖、迁移和侵袭

下载PDF
导出
摘要 目的基于网络药理学方法探讨金丝桃苷治疗乳腺癌的靶点及作用机制,并通过体外和体内实验进行验证。方法通过SwissTarget和TargetNet数据库获取金丝桃苷作用靶点,通过GeneCards数据库获取乳腺癌疾病相关靶点;利用STRING平台构建蛋白质相互作用(PPI)网络;基于肿瘤基因组图谱(TCGA)数据库分析交集靶点基因与乳腺癌临床表型的关系。采用CCK-8实验及异种移植实验观察金丝桃苷对乳腺癌细胞体外和体内增殖的影响;采用Transwell实验和划痕实验观察金丝桃苷对乳腺癌细胞侵袭和迁移的影响;构建热休克蛋白(HSP)90α家族A类成员(HSP90AA)1过表达质粒并转染人乳腺癌细胞系MCF-7和MDA-MB-231,观察上调HSP90AA1表达对乳腺癌增殖、侵袭及迁移的影响。结果基于网络药理学的分析显示,金丝桃苷作用于乳腺癌的靶点共有包括HSP90AA1在内的25个靶点;TCGA数据库的临床数据表明,HSP90AA1在乳腺癌癌组织中的表达较正常乳腺组织表达明显上调(P<0.05),且其高表达与临床分期晚及预后差密切相关(P<0.05)。功能实验中,金丝桃苷显著抑制乳腺癌细胞的增殖、迁移和侵袭(P<0.05),并能明显抑制裸鼠乳腺癌癌移植瘤的生长(P<0.05)。金丝桃苷呈剂量依赖性抑制HSP90AA1蛋白表达(P<0.05),使用HSP90AA1过表达质粒上调HSP90AA1表达则明显逆转金丝桃苷的以上抑癌作用(P<0.05)。结论HSP90AA1在乳腺癌表达上调,并与乳腺癌的不良预后密切相关;金丝桃苷可通过抑制HSP90AA1抑制乳腺癌增殖、迁移和侵袭。
出处 《中国老年学杂志》 CAS 北大核心 2023年第21期5271-5276,共6页 Chinese Journal of Gerontology
基金 2019年河南省医学教育研究项目(Wjlx2019257)。
  • 相关文献

参考文献2

二级参考文献40

  • 1Kaur A,Dasanu C A. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma[J].{H}EXPERT OPINION ON PHARMACOTHERAPY,2011,(16):2493-2503.
  • 2Mukohara T. Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer[J].Chemother Res Pract,2011.730360.
  • 3Saxena R,Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer:current status and future clinical perspective[J].{H}Medicinal Research Reviews,2012,(01):166-215.
  • 4Mukai H. Treatment strategy for HER2-positive breast cancer[J].{H}International Journal of Clinical Oncology,2010,(04):335-340.
  • 5Slamon D J,Leyland Jones B,Shak S. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2[J].{H}New England Journal of Medicine,2001,(11):783-792.
  • 6Extra J M,Cognetti F,Chan S. 672 Randomised phase Ⅱ trial (M77001) of trastuzumab (Herceptin(R[J].{H}EUROPEAN JOURNAL OF CANCER,2003,(05):S202.
  • 7Von Minckwitz G,Zielinski C,Maarteense E. Capecitabine vs.capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment:The TBP phase Ⅲ study (GBG 26/BIG 3-05)[J].{H}Journal of Clinical Oncology,2008,(15):1025.
  • 8Kaufman B,Mackey J R,Clemens M R. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive,hormone receptor-positive metastatic breast cancer:results from the randomized phase Ⅲ TAnDEM study[J].{H}Journal of Clinical Oncology,2009,(33):5529-5537.
  • 9Jones K L,Buzdar A U. Evolving novel anti-HER2 strategies[J].{H}LANCET ONCOLOGY,2009,(12):1179-1187.
  • 10Baselga J,Gelmon K A,Verma S. Phase Ⅱ trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy[J].{H}Journal of Clinical Oncology,2010,(07):1138-1144.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部